Exelixis Company Profile (NASDAQ:EXEL)

About Exelixis

Exelixis, Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. It is evaluating Cabozantinib in a development program, which consists of over 45 clinical trials, across multiple indications, including pivotal studies in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Its other products are Cobimetinib and XL888. Cobimetinib is a potent, selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein that affects the activity and stability of a range of regulatory proteins.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: Biotechnology
Exchange: NASDAQ
Symbol: EXEL
CUSIP: 30161Q10

Key Metrics:

Previous Close: $15.31
50 Day Moving Average: $11.87
200 Day Moving Average: $7.56
52-Week Range: $3.55 - $15.46
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -153.10
P/E Growth: 1.00
Market Cap: $3.53B
Outstanding Shares: 230,325,000
Beta: 2.14

Profitability:

Net Margins: -265.24%
Return on Assets: -45.53%

Debt:

Debt-to-Equity Ratio: -1.55%
Current Ratio: 1.83%
Quick Ratio: 1.82%

Additional Links:

Companies Related to Exelixis:

Consensus Ratings for Exelixis (NASDAQ:EXEL) (?)

Ratings Breakdown:	1 Hold Rating, 4 Buy Ratings
Consensus Rating:	Buy (Score: 2.80)
Consensus Price Target:	$11.67 (23.80% downside)

Analysts' Ratings History for Exelixis (NASDAQ:EXEL)

Show:

Date	Firm	Action	Rating	Price Target
9/20/2016	Leerink Swann	Reiterated Rating	Outperform	$12.00
9/15/2016	Stifel Nicolaus	Boost Price Target	Buy	$12.00 -> $15.00
9/15/2016	William Blair	Reiterated Rating	Outperform
8/10/2016	Cowen and Company	Reiterated Rating	Buy
8/4/2016	Piper Jaffray Cos.	Reiterated Rating	Neutral	$5.00 -> $8.00

(Data available from 9/26/2014 forward)

Earnings History for Exelixis (NASDAQ:EXEL)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/8/2016
8/3/2016	Q216	($0.27)	($0.16)	$16.76 million	$36.25 million	View	Listen
5/4/2016	Q116	($0.25)	($0.27)	$9.11 million	$15.40 million	View	Listen
2/29/2016	Q415	($0.22)	($0.19)	$8.16 million	$9.94 million	View	Listen
11/10/2015	Q315	($0.20)	($0.22)	$9.08 million	$9.85 million	View	Listen
8/11/2015	Q215	($0.21)	($0.22)	$8.69 million	$8.00 million	View	Listen
4/30/2015	Q115	($0.24)	($0.18)	$8.08 million	$9.40 million	View	Listen
2/24/2015	Q414	($0.31)	($0.30)	$7.50 million	$7.35 million	View	Listen
11/4/2014	Q314	($0.37)	($0.32)	$6.77 million	$6.30 million	View	Listen
7/31/2014	Q214	($0.39)	($0.38)	$5.66 million	$6.56 million	View	Listen
5/1/2014	Q114	($0.37)	($0.39)	$6.11 million	$4.90 million	View	Listen
2/20/2014	Q413	($0.38)	($0.38)	$5.71 million	$4.34 million	View	Listen
10/30/2013	Q313	($0.37)	($0.36)	$5.55 million	$5.50 million	View	Listen
8/6/2013	Q2 2013	($0.30)	($0.34)	$6.55 million	$11.90 million	View	Listen
5/7/2013	Q1 2013	($0.29)	($0.24)	$5.33 million	$9.70 million	View	Listen
2/21/2013	Q4 2012	($0.24)	($0.28)	$9.46 million	$7.80 million	View	Listen
11/7/2012	Q312	($0.30)	($0.20)	$9.22 million	$13.30 million	View	N/A
8/2/2012		($0.27)	($0.25)			View	N/A
5/3/2012		($0.19)	($0.18)			View	N/A
10/27/2011		$0.57	$0.60			View	N/A
8/4/2011		($0.17)	($0.16)			View	N/A
5/3/2011		($0.19)	($0.24)			View	N/A
2/22/2011		($0.21)	($0.16)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Exelixis (NASDAQ:EXEL)

Current Year EPS Consensus Estimate: $-0.62 EPS
Next Year EPS Consensus Estimate: $-0.10 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	2	($0.27)	($0.24)	($0.26)
Q2 2016	2	($0.29)	($0.28)	($0.29)
Q3 2016	2	($0.11)	($0.07)	($0.09)
Q4 2016	2	($0.04)	($0.02)	($0.03)
Q1 2017	1	$0.00	$0.00	$0.00
Q2 2017	1	($0.01)	($0.01)	($0.01)
Q3 2017	1	$0.01	$0.01	$0.01
Q4 2017	1	$0.04	$0.04	$0.04

(Data provided by Zacks Investment Research)

Dividend History for Exelixis (NASDAQ:EXEL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Exelixis (NASDAQ:EXEL)

Insider Ownership Percentage: 5.90%
Institutional Ownership Percentage: 81.80%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/4/2016	Gisela Schwab	Insider	Sell	42,338	$11.00	$465,718.00
5/11/2016	Lance Willsey	Director	Buy	60,000	$4.97	$298,200.00
5/9/2016	Lance Willsey	Director	Buy	40,000	$4.97	$198,800.00
12/11/2015	Lance Willsey	Director	Buy	100,000	$4.89	$489,000.00
10/16/2015	Peter Lamb	EVP	Sell	51,549	$5.80	$298,984.20
10/13/2015	Peter Lamb	EVP	Sell	600	$5.80	$3,480.00
10/12/2015	Peter Lamb	EVP	Sell	300,276	$5.84	$1,753,611.84
9/17/2014	Vincent T Marchesi	Director	Buy	20,000	$1.71	$34,200.00
8/29/2013	Lance Willsey	Director	Buy	10,000	$5.15	$51,500.00
12/20/2012	Vincent T Marchesi	Director	Buy	4,000	$4.68	$18,720.00
12/19/2012	Vincent T Marchesi	Director	Buy	6,000	$4.72	$28,320.00
12/10/2012	Gisela Schwab	EVP	Buy	25,000	$4.39	$109,750.00

(Data available from 1/1/2013 forward)

Latest Headlines for Exelixis (NASDAQ:EXEL)

Date	Headline
	Analysts Valuations For Two Stocks: Exelixis, Inc. (NASDAQ:EXEL), Pitney Bowes Inc. (NYSE:PBI) - The Voice Registrar (NASDAQ:EXEL) voiceregistrar.com - September 26 at 5:03 PM
	Overbuying Activity: Exelixis, Inc. (NASDAQ:EXEL) - Post Registrar (NASDAQ:EXEL) postregistrar.com - September 26 at 5:03 PM
	Stock Update (NASDAQ:EXEL): Exelixis, Inc. Announces Collaborator Daiichi Sankyo's Initiation of Phase 3 Clinical ... - Smarter Analyst (NASDAQ:EXEL) www.smarteranalyst.com - September 26 at 5:03 PM
	EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:EXEL) biz.yahoo.com - September 26 at 5:03 PM
	Exelixis Elects Julie Anne Smith to Its Board of Directors - Business Wire (press release) (NASDAQ:EXEL) www.businesswire.com - September 26 at 9:40 AM
	Stock under Radar: eBay Inc. (NASDAQ:EBAY), Exelixis, Inc ... - Newburgh Press (NASDAQ:EXEL) newburghpress.com - September 26 at 9:40 AM
	Exelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor Antagonist (NASDAQ:EXEL) www.publicnow.com - September 26 at 9:40 AM
	Exelixis Elects Julie Anne Smith to Its Board of Directors (NASDAQ:EXEL) www.publicnow.com - September 26 at 9:40 AM
	Surging Earnings Estimates Signal Good News for Exelixis (EXEL) (NASDAQ:EXEL) finance.yahoo.com - September 26 at 9:40 AM
	Cramer: I overstayed my welcome on this stock (NASDAQ:EXEL) www.cnbc.com - September 23 at 4:43 PM
	News review of 2 biotech stocks: Novavax, Inc. (NASDAQ:NVAX), Exelixis, Inc. (NASDAQ:EXEL) - The Voice Registrar (NASDAQ:EXEL) voiceregistrar.com - September 22 at 10:30 AM
	Analysts Chime In On Exelixis, Inc. (NASDAQ:EXEL) - Post Registrar (NASDAQ:EXEL) postregistrar.com - September 22 at 10:30 AM
	4:56 pm Exelixis will provide update on CABOzantinib in clinical data oral presentation at the ESMO Congress on Oct 10 at 10:30am ET (previously scheduled for Oct 8) (NASDAQ:EXEL) finance.yahoo.com - September 22 at 10:30 AM
	2 Biotech Stocks News And Price Trends: Exelixis, Inc. (NASDAQ:EXEL), Galena Biopharma, Inc. (NASDAQ:GALE) - The Voice Registrar (NASDAQ:EXEL) voiceregistrar.com - September 21 at 5:26 PM
	Overbuying Alert on: Exelixis, Inc. (NASDAQ:EXEL) - Post Registrar (NASDAQ:EXEL) postregistrar.com - September 21 at 5:26 PM
	Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016 Congress (NASDAQ:EXEL) www.businesswire.com - September 21 at 9:09 AM
	HC Stocks in Hub! Exelixis, Inc. (EXEL), Johnson & Johnson (NYSE:JNJ) - share market updates (press release) (NASDAQ:EXEL) sharemarketupdates.com - September 20 at 8:47 AM
	Analysts Valuations For Two Stocks: Genworth Financial Inc (NYSE:GNW), Exelixis, Inc. (NASDAQ:EXEL) - The Voice Registrar (NASDAQ:EXEL) voiceregistrar.com - September 20 at 8:47 AM
	William Blair Dives in on Exelixis, Inc. (EXEL) Ahead of Phase II CABOSUN Data - Smarter Analyst (NASDAQ:EXEL) www.smarteranalyst.com - September 18 at 9:34 AM
	Exelixis, Inc. (EXEL) Stock Soars to 10-Year High After CABOMETYX Approval (NASDAQ:EXEL) www.bidnessetc.com - September 16 at 4:49 PM
	Exelixis Inc reiterated as Buy By Stifel Nicolaus (NASDAQ:EXEL) larampadinapoli.com - September 16 at 4:49 PM
	William Blair Dives in on Exelixis, Inc. (EXEL) Ahead of Phase II CABOSUN Data (NASDAQ:EXEL) www.smarteranalyst.com - September 16 at 4:49 PM
	Stocks In Action: Exelixis, Inc. (EXEL), Cliffs Natural Resources Inc. (CLF), Sysco Corporation (SYY) - iStreetWire (NASDAQ:EXEL) istreetwire.com - September 15 at 5:20 PM
	Biotech news that matter for investors: Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB), Exelixis, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:EXEL) voiceregistrar.com - September 15 at 5:20 PM
	Stock Grabbing Investor's Attention: Exelixis, Inc. (NASDAQ:EXEL) - Post Registrar (NASDAQ:EXEL) postregistrar.com - September 15 at 5:20 PM
	Will Exelixis (EXEL) Continue to Surge Higher? (NASDAQ:EXEL) finance.yahoo.com - September 15 at 5:20 PM
	Stocks Tossing up on Optimistic Data: Exelixis, Inc. (NASDAQ:EXEL), Agilent Technologies, Inc. (NYSE:A) - Street Wise Report (press release) (blog) (NASDAQ:EXEL) streetwisereport.com - September 15 at 5:04 AM
	Exelixis Wins EU Approval for Cabometyx RCC Treatment (EXEL) (NASDAQ:EXEL) www.investopedia.com - September 14 at 10:08 PM
	European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following... (NASDAQ:EXEL) ih.advfn.com - September 14 at 5:01 PM
	Exelixis (EXEL) Receives EC Approval of CABOMETYX as RCC Treatment Following VEGF-Targeted Therapy (NASDAQ:EXEL) www.streetinsider.com - September 14 at 5:01 PM
	Exelixis Shares Soar on Cancer Therapies (EXEL) (NASDAQ:EXEL) www.investopedia.com - September 14 at 5:01 PM
	European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy (NASDAQ:EXEL) finance.yahoo.com - September 14 at 5:01 PM
	Exelixis, Ipsen say EU approves kidney cancer drug (NASDAQ:EXEL) www.marketwatch.com - September 14 at 5:01 PM
	Stock Update (NASDAQ:EXEL): Exelixis, Inc.’s CABOMETYX Approved by the European Commission for the Treatment of Advanced Renal Cell Carcinoma (NASDAQ:EXEL) www.smarteranalyst.com - September 14 at 5:01 PM
	Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar (NASDAQ:EXEL) www.investors.com - September 14 at 5:01 PM
	HC Stocks Updates= Unilife Corp (UNIS), Exelixis, Inc. (NASDAQ:EXEL) - share market updates (press release) (NASDAQ:EXEL) sharemarketupdates.com - September 14 at 9:06 AM
	Stock Update (NASDAQ:EXEL): Exelixis, Inc.'s CABOMETYX Approved by the European Commission for the Treatment ... - Smarter Analyst (NASDAQ:EXEL) www.smarteranalyst.com - September 14 at 9:06 AM
	Exelixis' Cabometyx approved in Europe for kidney cancer; shares up 1% premarket (NASDAQ:EXEL) seekingalpha.com - September 14 at 7:53 AM
	Analysts Taking Ride on Hard Facts For- Exelixis, Inc. (NASDAQ:EXEL), Catalent, Inc. (NYSE:CTLT) - Seneca Globe (NASDAQ:EXEL) www.senecaglobe.com - September 11 at 4:39 PM
	Top Earnings to Watch for: Exelixis, Inc. (NASDAQ:EXEL) - The Voice Registrar (NASDAQ:EXEL) voiceregistrar.com - September 9 at 4:49 PM
	Analysts Advise About Exelixis, Inc. (NASDAQ:EXEL) - National Daily Press (NASDAQ:EXEL) www.nationaldailypress.com - September 9 at 4:49 PM
	Intraday Active Biotech Stocks News: Exelixis, Inc. (NASDAQ:EXEL ... - The Voice Registrar (NASDAQ:EXEL) voiceregistrar.com - September 9 at 4:49 PM
	Stock Update (NASDAQ:EXEL): Exelixis, Inc. Announces Outcome from First ... (NASDAQ:EXEL) www.smarteranalyst.com - September 9 at 9:45 AM
	HC Stocks Alerts= Esperion Therapeutics Inc (ESPR), Exelixis, Inc. (NASDAQ:EXEL) - share market updates (press release) (NASDAQ:EXEL) sharemarketupdates.com - September 8 at 8:48 AM
	The Clear Reason Behind Exelixis, Inc.'s 21% Gain in August - Motley Fool (NASDAQ:EXEL) www.fool.com - September 8 at 8:48 AM
	Key FDA Decisions and Trial Results Expected in October (NASDAQ:EXEL) 247wallst.com - September 8 at 8:48 AM
	The Clear Reason Behind Exelixis, Inc.'s 21% Gain in August (NASDAQ:EXEL) www.fool.com - September 8 at 8:48 AM
	Biotechnology Stocks to Lookout: Navidea Biopharmaceuticals Inc (NYSEMKT: NAVB), Exelixis, Inc. (NASDAQ:EXEL) - Post Registrar (NASDAQ:EXEL) postregistrar.com - September 7 at 5:04 PM
	Insider Trading Activity: Exelixis, Inc. (NASDAQ:EXEL) - Post Registrar - Post Registrar (NASDAQ:EXEL) postregistrar.com - September 7 at 8:17 AM
	Stock Update (NASDAQ:EXEL): Exelixis, Inc. Announces Outcome from First Planned Interim Analysis of the Phase 3 ... - Smarter Analyst (NASDAQ:EXEL) www.smarteranalyst.com - September 7 at 8:17 AM